BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Imamura H, Ikeda M, Furukawa H, Tsujinaka T, Fujitani K, Kobayashi K, Narahara H, Kato M, Imamoto H, Takabayashi A, Tsukuma H. Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer. World J Gastroenterol 2006; 12(40): 6522-6526 [PMID: 17072984 DOI: 10.3748/wjg.v12.i40.6522]
URL: https://www.wjgnet.com/1007-9327/full/v12/i40/6522.htm
Number Citing Articles
1
Hannah Kenward, Ludovic Pelligand, Jonathan Elliott. Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administrationExperimental Brain Research 2014; 232(8): 2685 doi: 10.1007/s00221-014-3961-6
2
Clinton F. Stewart, John C. Panetta, Melinda A. O'Shaughnessy, Stacy L. Throm, Charles H. Fraga, Thandranese Owens, Tiebin Liu, Catherine Billups, Carlos Rodriguez-Galindo, Amar Gajjar, Wayne L. Furman, Lisa M. McGregor. UGT1A1Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose IrinotecanJournal of Clinical Oncology 2007; 25(18): 2594 doi: 10.1200/JCO.2006.10.2301
3
Paul G. Tardi, Nancy Dos Santos, Troy O. Harasym, Sharon A. Johnstone, Natalia Zisman, Alan W. Tsang, David G. Bermudes, Lawrence D. Mayer. Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo Molecular Cancer Therapeutics 2009; 8(8): 2266 doi: 10.1158/1535-7163.MCT-09-0243